{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Oncology+Care&page=50", "query": { "intervention": "Standard Oncology Care", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 3315, "total_pages": 332, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Oncology+Care&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+Oncology+Care&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T05:01:42.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01921751", "title": "High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "low intensity radiation therapy", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "high intensity radiation therapy", "type": "RADIATION" }, { "name": "nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 46, "location_summary": "Oakland, California • Santa Clara, California • South San Francisco, California + 39 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Santa Clara", "state": "California" }, { "city": "South San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921751" }, { "nct_id": "NCT05893888", "title": "A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Oral Squamous Cell Carcinoma" ], "interventions": [ { "name": "PRV211 (Intraoperative Cisplatin System)", "type": "DRUG" }, { "name": "PRV111 (Cisplatin Transmucosal System)", "type": "DRUG" }, { "name": "PRV131 (Cisplatin Intratumoral Injectable)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Privo Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2024-11-07", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 4, "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05893888" }, { "nct_id": "NCT06995703", "title": "Increasing Screening for Cancer Using EHR-Nudges Replication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pre-Visit Patient Text Message", "type": "BEHAVIORAL" }, { "name": "Post-Visit Patient Text Messages", "type": "BEHAVIORAL" }, { "name": "Smart Data Element (SDE)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "40 Years to 74 Years · Female only" }, "enrollment_count": 8490, "start_date": "2025-06-02", "completion_date": "2026-06-02", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "Lancaster, Pennsylvania", "locations": [ { "city": "Lancaster", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995703" }, { "nct_id": "NCT04045470", "title": "A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous T Cell Lymphoma", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Microdevices", "type": "DEVICE" }, { "name": "Standard of care therapy", "type": "OTHER" }, { "name": "Standard of care systemic therapy", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-12-11", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04045470" }, { "nct_id": "NCT07662031", "title": "Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Tovecimig", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-08-31", "completion_date": "2032-08-31", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07662031" }, { "nct_id": "NCT00266331", "title": "RayGel-An Alternative for Skin Care During External Beam Radiation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Reduced glutathione", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nathalie Johnson", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2004-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266331" }, { "nct_id": "NCT04614194", "title": "Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Letrozole", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2021-04-15", "completion_date": "2028-04-15", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614194" }, { "nct_id": "NCT05086731", "title": "Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Localized Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2021-10-22", "completion_date": "2024-03-06", "has_results": false, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086731" }, { "nct_id": "NCT04614766", "title": "A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "Azedra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Bushnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2022-09-30", "completion_date": "2024-04-23", "has_results": false, "last_update_posted_date": "2024-04-29", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614766" }, { "nct_id": "NCT06586255", "title": "Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma Bladder", "Bladder Cancer" ], "interventions": [ { "name": "Concurrent Immunotherapy and Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-04-29", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-20T05:01:42.678Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586255" } ] }